Navigation Links
Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
Date:9/24/2009

Research & development 1,464 952 ----- --- Total other expenses 10,326 9,151 ------ ----- Operating income 6,944 5,653 Other revenue 51 205 Income before tax 6,995 5,858 Income tax 2,600 2,125 ----- ----- Net income $4,395 $3,733 Net income per diluted share $0.29 $0.25 Other information: Shares to calculate per share 15,257 15,031 Depreciation & amortization $1,012 $948 Interest income 17 65 Gross margin (% of sales) 53.4% 51.4% Operating income (% of sales) 21.5% 19.6% Revenue increase vs. FY 2009 12.3% Net income increase vs. FY 2009 17.7%

    NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED
    BALANCE SHEET DATA
    (In thousands)


                                                 Aug. 31      May 31
                                                    2009        2009
    Assets
     Current assets
             Cash & investments                  $23,564     $13,842
             Accounts receivable                  24,094      23,363
             Inventory                            30,471      31,363
             Other current assets                  3,074       3,198
                                                   -----       -----
     Total current assets                         81,203      71,766
     Property & equipment                         17,265      17,058
     Goodwill & other assets                      53,
'/>"/>
SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neogen Acquires Kane Enterprises
2. Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues
3. Neogen Acquires Assets of Rivard Instruments
4. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
5. Neogen Launches Quickest Test Available for Tetracyclines in Milk
6. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
7. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
8. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
9. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
10. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
11. Neogen Forms Mexican Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. ... (eslicarbazepine acetate) for use as a once-daily adjunctive ... with epilepsy who are not satisfactorily controlled with conventional ... in patients under 18 years of age. ... disorders and according to Epilepsy Canada, it affects 0.6% ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... YORK, Oct. 23 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... notice from The,Nasdaq Stock Market ("Nasdaq") stating that ... a minimum bid price of,$1.00 per share, has ... the Company that it now has until January ...
... Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... abstract entitled "Phase I Trial,of Oncolytic Reovirus ... Advanced Solid Cancers" will be,available in the ... official journal of the International Society for ...
... Md., Oct. 23 MedImmune today announced,that researchers ... at the Annual Meeting of the American College ... the Moscone Center in San Francisco, California., ... solutions for patients,struggling with systemic autoimmune rheumatic diseases," ...
Cached Biology Technology:Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 2Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting 3MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 2MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology 3
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... and monkeys don,t develop diseases in the same way that ... in a Petri dish, they have little choice but to ... of Washington bioengineers have developed the first structure to grow ... offers a better way to study disease, test drugs and ...
... It took some 10 million years for Earth to recover ... has revealed., Life was nearly wiped out 250 million years ... surviving. It is currently much debated how life recovered from ... rapid bounce-back is evaluated in a new review article by ...
... of red blood cells (RBC) is a critical ... acute and chronic medical problems. Indeed, approximately 75 ... are annually collected worldwide for processing and eventual ... for blood constantly exceeds availability due to a ...
Cached Biology News:Engineered microvessels provide a 3-D test bed for human diseases 210 million years to recover from mass extinction 2Proteomic analysis of immunocamouflaged surfaces 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
...
... These 2-D standards consist of seven ... inhibitor, bovine carbonic anhydrase, rabbit muscle GAPDH, ... white conalbumin) with pIs ranging from 4.5 ... 17,500 to 76,000. These 2-D standards provide ...
... tube gel adaptors, 24 glass tubes (1.5 ... stoppers. The PROTEAN II xi cell and ... versatility to perform a variety of separations,* ... native, preparative, and gradient PAGE as well ...
Biology Products: